Research map: Pragmatic Management of EGFR-Mutant NSCLC After Progression on Osimertinib: Canadian Expert Perspectives

Back to the article

Papers in this map

  1. Osimertinib in Untreated EGFR -Mutated Advanced Non–Small-Cell Lung Cancer · Jean‐Charles Soria · 2017 · 5482 citations · Cited by this paper
  2. Prognostic Value of the Systemic Immune-Inflammation Index in Advanced Endometrial Cancer Treated with Pembrolizumab–Lenvatinib: A Retrospective Real-World Study · 2026 · Related
  3. Overall Survival with Osimertinib in Untreated, EGFR -Mutated Advanced NSCLC · Suresh S. Ramalingam · 2019 · 2942 citations · Cited by this paper
  4. Trastuzumab Deruxtecan in Metastatic Urothelial Carcinoma with NGS-Detected ERBB2 Amplification: A Four-Patient Real-World Case Series · 2026 · Related
  5. Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer · Alessandro Leonetti · 2019 · 1444 citations · Cited by this paper
  6. Early Adherence to Immunomodulators in Multiple Myeloma: Retrospective Observations from a Safety-Net Hospital · 2026 · Related
  7. Osimertinib with or without Chemotherapy in EGFR -Mutated Advanced NSCLC · David Planchard · 2023 · 732 citations · Cited by this paper
  8. Magnetic Resonance-Guided Radiotherapy for Unresectable Hepatocellular Carcinoma with Bile Duct Tumor Thrombus: A Case Series and Review of Treatment Options · 2026 · Related
  9. Defining oligometastatic disease from a radiation oncology perspective: An ESTRO-ASTRO consensus document · Yolande N. Lievens · 2020 · 679 citations · Cited by this paper
  10. Hyperbaric Oxygen Therapy for Late Radiation-Induced Duodenal Toxicity After Stereotactic Body Radiotherapy in a Patient with Cholangiocellular Carcinoma: A Unique Case Report · 2026 · Related
  11. EGFR -Mutant Adenocarcinomas That Transform to Small-Cell Lung Cancer and Other Neuroendocrine Carcinomas: Clinical Outcomes · Nicolas Marcoux · 2018 · 504 citations · Cited by this paper
  12. Older Age Does Not Have an Impact on Postoperative Complication Risk Following Transurethral Resection of the Bladder Tumor · 2026 · Related
  13. Amivantamab plus Lazertinib in Previously Untreated EGFR -Mutated Advanced NSCLC · Byoung Chul Cho · 2024 · 453 citations · Cited by this paper
  14. ESR1 Y537S Detected in a Brain Metastasis but Not in Plasma ctDNA in HR+/HER2-Low Metastatic Breast Cancer: A Case Report · 2026 · Related
  15. Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study · Antonio Passaro · 2023 · 438 citations · Cited by this paper
  16. The Efficacy of Transcutaneous Electrical Acupoint Stimulation as an Adjunct to Standard Bladder Training for Bladder Emptying After Radical Hysterectomy for Cervical Cancer: A Randomized Controlled Trial · 2026 · Related
  17. Tumor Analyses Reveal Squamous Transformation and Off-Target Alterations As Early Resistance Mechanisms to First-line Osimertinib in EGFR -Mutant Lung Cancer · Adam Jacob Schoenfeld · 2020 · 411 citations · Cited by this paper
  18. Response to Zona, E.E.; Israel, J.S. Toward Individualized Management: A Commentary on Perioperative Systemic Therapy Guidelines in Breast Cancer Surgery and Reconstruction. Comment on “Galuia et al. Perioperative Drug Management of Systemic Therapies in Breast Cancer: A Literature Review and Treatment Recommendations. Curr. Oncol. 2025, 32, 154” · 2026 · Related
  19. IMpower150 Final Exploratory Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in Key NSCLC Patient Subgroups With EGFR Mutations or Metastases in the Liver or Brain · Naoyuki Nogami · 2021 · 315 citations · Cited by this paper
  20. Liquid biopsy for the management of NSCLC patients under osimertinib treatment · 2024 · Related
  21. HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor–Mutated Non–Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based Chemotherapy · Helena Alexandra Yu · 2023 · 245 citations · Cited by this paper
  22. Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non–Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 Study · Myung‐Ju Ahn · 2024 · 228 citations · Cited by this paper
  23. ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancer · Antonio Passaro · 2022 · 204 citations · Cited by this paper
  24. Ivonescimab Plus Chemotherapy in Non–Small Cell Lung Cancer With EGFR Variant · HARMONi-A Study Investigators · 2024 · 198 citations · Cited by this paper
  25. Nivolumab Plus Chemotherapy in Epidermal Growth Factor Receptor–Mutated Metastatic Non–Small-Cell Lung Cancer After Disease Progression on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: Final Results of CheckMate 722 · Tony S.K. Mok · 2024 · 163 citations · Cited by this paper
  26. Phase III KEYNOTE-789 Study of Pemetrexed and Platinum With or Without Pembrolizumab for Tyrosine Kinase Inhibitor‒Resistant, EGFR –Mutant, Metastatic Nonsquamous Non–Small Cell Lung Cancer · James Chih‐Hsin Yang · 2024 · 158 citations · Cited by this paper
  27. Overall Survival with Amivantamab–Lazertinib in EGFR -Mutated Advanced NSCLC · James Chih‐Hsin Yang · 2025 · 136 citations · Cited by this paper
  28. Osimertinib Resistance: Molecular Mechanisms and Emerging Treatment Options · Georgia Gomatou · 2023 · 134 citations · Cited by this paper
  29. Antibody-drug conjugates in lung cancer: dawn of a new era? · Niamh Coleman · 2023 · 130 citations · Cited by this paper
  30. Survival with Osimertinib plus Chemotherapy in EGFR -Mutated Advanced NSCLC · Pasi Antero Janne · 2025 · 106 citations · Cited by this paper
  31. Tepotinib plus osimertinib in patients with EGFR-mutated non-small-cell lung cancer with MET amplification following progression on first-line osimertinib (INSIGHT 2): a multicentre, open-label, phase 2 trial · Yi-Long Lung Cancer Wu · 2024 · 105 citations · Cited by this paper
  32. Sacituzumab Tirumotecan in EGFR-TKI–Resistant, EGFR -Mutated Advanced NSCLC · Wenfeng Fang · 2025 · 71 citations · Cited by this paper
  33. The study of primary and acquired resistance to first-line osimertinib to improve the outcome of EGFR-mutated advanced Non-small cell lung cancer patients: the challenge is open for new therapeutic strategies · Alessandra Ferro · 2024 · 69 citations · Cited by this paper
  34. Systemic Therapy for Small-Cell Lung Cancer: ASCO-Ontario Health (Cancer Care Ontario) Guideline · Humera Khurshid · 2023 · 57 citations · Cited by this paper
  35. A Pooled Analysis of Datopotamab Deruxtecan in Patients With EGFR-Mutated NSCLC · Myung‐Ju Ahn · 2025 · 57 citations · Cited by this paper
  36. Savolitinib plus osimertinib in epidermal growth factor receptor (EGFR)-mutated advanced non-small cell lung cancer with MET overexpression and/or amplification following disease progression on osimertinib: primary results from the phase II SAVANNAH study · Filippo de Marinis · 2025 · 56 citations · Cited by this paper
  37. Patritumab deruxtecan (HER3-DXd) in resistant EGFR -mutated ( EGFR m) advanced non-small cell lung cancer (NSCLC) after a third-generation EGFR TKI: The phase 3 HERTHENA-Lung02 study. · Tony S.K. Mok · 2025 · 47 citations · Cited by this paper
  38. Current and future applications of liquid biopsy in non-small-cell lung cancer—a narrative review · Bartłomiej Tomasik · 2023 · 44 citations · Cited by this paper
  39. Results from a phase Ib study of telisotuzumab vedotin in combination with osimertinib in patients with c-Met protein-overexpressing, EGFR-mutated locally advanced/metastatic non-small-cell lung cancer (NSCLC) after progression on prior osimertinib · H. Horinouchi · 2025 · 44 citations · Cited by this paper

Source: OpenAlex (CC0)